SAB Biotherapeutics (SABS) Operating Leases (2020 - 2026)

SAB Biotherapeutics has reported Operating Leases for 7 years, with the latest figure at $2.2 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 12.01% year-over-year to $2.2 million; the trailing twelve-month figure through Mar 2026 stood at $2.2 million (down 12.01% YoY), and the FY2025 full-year result was $1.9 million, up 223.04% from the prior year.
• Operating Leases for Q1 2026 stood at $2.2 million, up from $1.9 million in the prior quarter.
• The five-year high for Operating Leases was $2.5 million in Q1 2025, with the low at $91816.0 in Q2 2023.
• Historically, Operating Leases has averaged $1.1 million across 5 years, with a median of $772605.0 in 2022.
• Annual changes were most pronounced in 2023 — Operating Leases sank 91.35% — and 2024, when it jumped 752.18%.
• SAB Biotherapeutics' Operating Leases stood at $361225.0 in 2022, then jumped by 76.01% to $635777.0 in 2023, then fell by 8.59% to $581148.0 in 2024, then jumped by 223.04% to $1.9 million in 2025, then increased by 15.64% to $2.2 million in 2026.
• The last three Operating Leases figures came in at $2.2 million (Q1 2026), $1.9 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.